| Ytd | -20.93% | |
| 1y | 95.07% |
| Open | 5.75 | Prev Close | 5.69 | Low | 5.74 | High | 6.02 | Mkt Cap | 191.48M |
| Vol | 12.90K | Avg Vol | 366.82K | EPS | -1.51 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 5.34 | 200-d Avg | 5.33 | 1yr Est | 0.00 |
IMDX News
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and t
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidn
NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD
NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD
Insight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks Transcript
NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMD
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the anal
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC re
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Im
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript
Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to sh
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the anal
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasd
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IM
NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMD
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today
GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-
Needham analyst Mike Matson maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the p
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.34) per share which missed the anal
American Journal of Transplantation study positions GraftAssure as potentially essential in managing
Insight Molecular Diagnostics, Inc. (NASDAQ:IMDX), ("iMDx"), today announced a positive stra
iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyG
Needham analyst Mike Matson reiterates Insight Molecular (NASDAQ:IMDX) with a Buy and maintains $
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.30) per share which missed the anal
iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combin